Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
http://img.marketwire.com/rss/mwPBBI.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announces  clinical  company  development  june  marketwired jun  marketwired june  marketwired  new  otc pink  pain  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech



Marketwired - Biotech



Last Build Date: Fri, 23 Jun 2017 17:35:17 EDT

Copyright: Copyright: (C) Marketwired
 



San Diego trade mission to Vancouver announces Phoenix Molecular Designs' expansion into the USA

Fri, 23 Jun 2017 16:45:29 EDT

VANCOUVER, BC--(Marketwired - June 23, 2017) - San Diego Mayor Kevin Faulconer is leading a trade mission of 26 delegates to Vancouver on Monday, June 26 to promote shared economic goals involving sustainable technologies and to promote partnership in building infrastructure in the life science sector.




Cosmos Holdings Signs Letter of Intent To Acquire CC Pharma GmbH A Leading Re-importer of EU Pharmaceuticals to Germany

Fri, 23 Jun 2017 15:44:30 EDT

CC Pharma GmbH had revenues of approximately $200M in 2016




Jacobson Pharma Announces 2017 Annual Results

Fri, 23 Jun 2017 12:33:38 EDT

Revenue Increases 15.9% to HK$1,256.0 Million; Adjusted Net Profit Up by 30.7% to HK$201.9 Million; Recommends a Final Dividend of HK1.4 Cents per Share




Cannabis Science Invests in the Research and Development of Cannabinoid-based Medications to Treat COPD and Asthma

Fri, 23 Jun 2017 09:14:44 EDT

IRVINE, CA--(Marketwired - Jun 23, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has invested in the research and development of new cannabinoid-based medications to treat Chronic Obstructive Pulmonary Disease (COPD) and Asthma. According to the Centers for Disease Control and Prevention, in the U.S. alone over 15 million people have been diagnosed with COPD, and over 25 million with Asthma.




Critical Outcome Technologies Announces Share Consolidation

Fri, 23 Jun 2017 08:30:00 EDT

LONDON, ON and BOSTON, MA--(Marketwired - June 23, 2017) - Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that in accordance with the approval of the Company's shareholders obtained on October 13, 2016, its Board of Directors has resolved to proceed with a consolidation of the Company's issued and outstanding common shares on the basis of ten pre-consolidation common shares for one post-consolidation common share (the "Consolidation"). The Consolidation will provide the Company flexibility with respect to attracting institutional investors that may otherwise be precluded from investing in securities trading below a certain price and support future equity financings.




Integrating Equipment Design, Logistics Processes and Real-Time Informatics: The Arrival of QbD in Pharmaceutical Logistics, New Webinar Hosted by Xtalks

Fri, 23 Jun 2017 07:30:00 EDT

Industry expert Mark W. Sawicki, Ph.D., chief commercial officer at Cryoport to discuss the Quality by Design process as it relates to logistics and evaluate its benefits during a live broadcast on Tuesday, July 11, 2017




Axiom Real-Time Metrics Showcasing Fusion eClinical Suite at the Outsourcing in Clinical Trials: Medical Devices 2017

Thu, 22 Jun 2017 15:46:27 EDT

TORONTO, ON--(Marketwired - June 22, 2017) - Axiom Real-Time Metrics, the premier provider of eClinical solutions and services to small to mid-sized life sciences organizations, is exhibiting at the Outsourcing in Clinical Trials: Medical Devices 2017 in Santa Clara, California, June 27-28, 2017. Axiom encourages attendees to join the team for a conversation over coffee at Booth 06.




Centralized Adaptive Trial Design Teams Facilitate Communication Between Global & Country-Level Pharma Teams

Thu, 22 Jun 2017 15:41:00 EDT

65% of surveyed global life science teams have a centralized adaptive trial reporting structure




ECPO-Subsidiary Immunotech Laboratories Enters Final Step of Full Commercialization by the BDA post Phase 3 Approval of ITV-1 for HIV/AIDS; Also Announces Issuance of Distribution Agreement for the Ukraine

Thu, 22 Jun 2017 13:24:33 EDT

MONROVIA, CA--(Marketwired - Jun 22, 2017) - Eco Petroleum Solutions, Inc. ((OTC PINK: ECPO) or the "Company") announces that IMMB BG a subsidiary of Immunotech Laboratories, Inc., the Company's subsidiary, has issued an exclusive Distribution Agreement (the "Agreement") for the territory of the Ukraine to LLC Project Development and Implementation Centre Omega ("Omega"). The term of the agreement is for an initial ten-year period with an option to renew the agreement for an additional ten years. The Agreement establishes a price of EUR 3,300 (Euros) per one 8-week cycle of injections or 16 vials. The treatment protocol requires two 8-week cycles of injections administered twice a week with a one-week break between cycles. The ITV-1 treatment will be administered with a combination of different variations of Protease Inhibitors used in the treatment of HIV/AIDS.




The Life Sciences Report Examines How a Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray

Thu, 22 Jun 2017 08:45:00 EDT

SAN FRANCISCO, CA--(Marketwired - June 22, 2017) - A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year.




UPDATE - Cannabis Science Releases the Chronic Pain CBIS Transdermal Patches to Meet the Overwhelming Demand from Self-Medicating Patients Worldwide as it Continues to Expands its California Dispensary Network

Thu, 22 Jun 2017 08:43:43 EDT

IRVINE, CA--(Marketwired - Jun 22, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its new product-development plans are well underway with the release of the first batch of the CBIS Transdermal Patch in response to an overwhelming response from hundreds chronic pain self-medicating patients worldwide with various chronic pain conditions including Neuropathy, Fibromyalgia, Diabetic Nerve Pain, Back Strains, and others.




VistaGen Announces Peer-Reviewed Publication in the Scandinavian Journal of Pain Highlighting Orally-Available AV-101's Excellent Safety Profile and Potential as a Non-Opioid Treatment for Neuropathic Pain

Thu, 22 Jun 2017 08:30:00 EDT

SOUTH SAN FRANCISCO, CA--(Marketwired - June 22, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today a peer-reviewed publication in the Scandinavian Journal of Pain of two Phase 1 clinical studies of the effects of AV-101 (4-Cl-KYN), the Company's CNS prodrug candidate, as a potential non-opioid treatment for neuropathic pain. Safety data from both the single and multi-dose Phase 1 studies indicated that oral AV-101 was extremely safe and well tolerated, with no meaningful difference in adverse events (AEs) at any dose between AV-101 and placebo. Recently published statistically-significant positive results in four well-established preclinical models of pain associated with tissue inflammation and nerve injury, together with the excellent clinical safety profile, pharmacokinetic (PK) characteristics and consistent reductions in three pain measures (allodynia, mechanical and heat hyperalgesia) demonstrated by these studies, support future Phase 2 clinical studies of AV-101 as a potential new non-opioid treatment alternative for neuropathic pain.




Cannabis Science Releases the Chronic Pain CBIS Transdermal Patches to Meet the Overwhelming Demand from Self-Medicating Patients Worldwide as it Continues to Expands its California Dispensary Network

Thu, 22 Jun 2017 08:11:45 EDT

IRVINE, CA--(Marketwired - Jun 22, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its new product-development plans are well underway with the release of the first batch of the CBIS Transdermal Patch in response to an overwhelming response from hundreds chronic pain self-medicating patients worldwide with various chronic pain conditions including Neuropathy, Fibromyalgia, Diabetic Nerve Pain, Back Strains, and others.




Lexaria Files New Patent Application

Thu, 22 Jun 2017 08:00:00 EDT

VANCOUVER, BC--(Marketwired - June 22, 2017) - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the filing of a new provisional patent application and stock and option awards.




Increasing Patient Enrollment and Patient Data Exchange: Digital Transformation in the Clinical Trial Process, New Webinar Hosted by Xtalks

Thu, 22 Jun 2017 07:30:00 EDT

Join this informative session as the speakers discuss ways to stimulate greater and faster recruitment as well as improve patient and research data harmonization and exchange, through a digital transformation




The Importance of Dose Prediction for Early Drug Development, New Webinar Hosted by Xtalks

Thu, 22 Jun 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - June 22, 2017) - During a live broadcast on Thursday, July 6, 2017, Dr. Robert Harris, Chief Technical Officer at Juniper Pharma Services and Dr. Graham Trevitt, Director (DMPK Consultancy, Modelling and Simulation) at XenoGesis will provide insight into how their joint consultative approach can help drug developers better understand the absorption and clearance characteristics of a drug substance and how these properties can influence dose prediction and selection of an appropriate formulation strategy.




Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)

Thu, 22 Jun 2017 05:30:00 EDT

Report on Impact of NB1111 on Tissues that Regulate Intraocular Pressure (IOP) in an Animal Normotensive Ocular Model




Tauriga Sciences Inc. Discloses Additional Personal Investment of $55,000 USD from its Chief Executive Officer Seth M. Shaw; Investment Structured as Equity Private Placement Priced at $0.00125

Wed, 21 Jun 2017 13:30:00 EDT

NEW YORK, NY--(Marketwired - Jun 21, 2017) - Tauriga Sciences Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company"), a company engaged in the building of life sciences businesses and technologies, has today announced that is Chief Executive Officer ("CEO"), Mr. Seth M. Shaw ("Mr. Shaw"), has made an additional personal investment into the Company totaling $55,000 USD at this time. This personal investment was once again structured as an equity Private Placement at a price of $0.00125 ("one eighth of one cent"), for a total of 44,000,000 shares (a Form 4 reflecting this insider purchase will be filed within the next several business days). Including the personal investment disclosed last week ($95,000 USD on June 15, 2017), Mr. Shaw has now invested a total of $150,000 USD into the Company at this price of $0.00125 per share; for a total of 120,000,000 shares. The Company will utilize this infusion of working capital for general and administrative purposes; these 44,000,000 shares will not be issued until the Company has successfully amended its Shares Authorized.




Clasado Biosciences to Exhibit at IFT17 Food Expo(R) in Las Vegas

Wed, 21 Jun 2017 11:34:49 EDT

Annual event brings together global innovators in the science of food




OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico

Wed, 21 Jun 2017 09:37:47 EDT

BATON ROUGE, LA--(Marketwired - June 21, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to report that that the Mexican Institute of Industrial Property has issued patent No. 343266, titled "Composition and Method for Treating Cancer," protecting the intellectual rights of OncBioMune's ProscaVax throughout Mexico until January 8, 2032.




NSAV to Launch Digital Insurance App With AMC Shanghai

Wed, 21 Jun 2017 09:20:00 EDT

CRESCO, PA--(Marketwired - Jun 21, 2017) - NSAV Holding, Inc. (OTC: NSAV) announced today that the Company will jointly develop a digital insurance app for the Chinese market with its local partner, AMC Shanghai. AMC's Medical Care and Insurance Division will be heading up the project along with NSAV's latest acquisition, Shanghai based Vital Strategic Research Institute. China's digital insurance market, which was $12.5 billion U.S. Dollars is 2015 is expected to soar to $136 billion U.S. Dollars by 2020.




Nutra Pharma Announcing Launch of Luxury Feet

Wed, 21 Jun 2017 08:30:00 EDT

Nutra Pharma is announcing the launch of Luxury Feet; an over-the-counter pain reliever for women who experience pain or discomfort due to high heels and stilettos




Rennova Health Stockholders Approve Proposal at Special Meeting

Wed, 21 Jun 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - June 21, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces that its stockholders approved Proposal 1 at a Special Meeting of Stockholders held on June 16, 2017.




Vitality Biopharma Advisor to Present Pediatric IBD Case Study at ICRS2017 in Montreal

Wed, 21 Jun 2017 08:30:00 EDT

Dr. Natasha Ryz, a Vitality research advisor, will present a case study report on cannabinoid treatment for pediatric Crohn's disease




CB Scientific (CBSC) Completing the Prototyping of Pain-Patch -- a Major Breakthrough in Cannabinoid Pain Alleviation Technology

Wed, 21 Jun 2017 08:00:00 EDT

DENVER, CO--(Marketwired - Jun 21, 2017) - CB Scientific, Inc. (OTC PINK: CBSC), a designer, developer and manufacturer of Cannabis Analytical Tools and Devices, Cannabis Medical Delivery Systems and Personal Analytical Kits and Devices, announces today that the Company has developed a novel product medical device portfolio since acquiring Marutronics Medical Devices in February 2017. The company has developed three core platform technologies; CannaRAPIDT, CannaNASALT, and CannaDERMET, focused on precise dosing and controlled release of cannabinoid compounds for patients.




Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer

Wed, 21 Jun 2017 07:30:00 EDT

Metabolic Inhibitor Shows Greater Ability to Kill Pancreatic Cancer Cell Lines




Delivra Appoints New Member to the Board of Directors and Stock Option Grant

Wed, 21 Jun 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - June 21, 2017) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company") announces the appointment of Ms. Louisa Greco, B.Ph., a pharmaceutical industry veteran, to the Company's Board of Directors. The Company also announces that Mr. David Mitchell has stepped down from the Board, effective immediately.

"We are excited about Louisa joining our Board. With a strong track-record of business leadership and growing consumer and pharmaceutical brands in Canada, Louisa will be a tremendous addition to our Board. We believe her deep experience and expertise broadly in healthcare and in consumer products will be invaluable as we advance our portfolio of products. We look forward to her contributions," said Dr. Joseph Gabriele, CEO of Delivra. We also wish to thank David for his contributions as a director, since the Company's public listing. He has been an asset to our Board and our business."




Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials

Wed, 21 Jun 2017 06:02:00 EDT

BEVERLY HILLS, CA--(Marketwired - Jun 21, 2017) - Rich Pharmaceuticals, Inc. (OTC PINK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology announced today its principal doctor, Dr. Tontanai Numbenjapon, will commence clinical trials in Phramongkutklao Hospital in Thailand.




Top Pharma Companies Look to Partnerships and Acquisitions to Maximize Resources During Product Development & Commercialization

Tue, 20 Jun 2017 17:57:00 EDT

Study finds that 60% of Top 10 pharma companies look to acquisitions to build their portfolios




Lattice Biologics Ltd. Announces Change to Location of Its Annual General and Special Meeting

Tue, 20 Jun 2017 16:30:00 EDT

SCOTTSDALE, AZ--(Marketwired - June 20, 2017) - Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") announces that due to increased shareholder interest it is changing the location of its Annual General and Special Meeting to accommodate greater attendance. The time and date of the meeting are unchanged. The meeting will now be held on June 30, 2017 at 10 a.m. Arizona Time at:




OncBioMune Awarded Patent for ProscaVax in Japan

Tue, 20 Jun 2017 14:11:19 EDT

BATON ROUGE, LA--(Marketwired - June 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, today announces that patent No. 6118730 has been granted by the Japan Patent Office.




CROS NT Launches CROScheck(TM) at DIA Chicago to Help Clinical Trial Sponsors Meet New ICH GCP E6(R2) Guidelines

Tue, 20 Jun 2017 13:14:41 EDT

Sponsors of clinical trials can now easily perform an independent check of the data quality coming in from sites at any time, contribute to a risk-based approach to monitoring and check follow-up by monitors of identified corrective actions




Bioz Launches Partner Program for Life Science Tool Vendors

Tue, 20 Jun 2017 09:00:00 EDT

Partner Program Members Granted Unparalleled Access to Worldwide Biopharma and University Life Science Researchers During Experimentation Planning Process




MCIG to Manage and Staff Indoor Grow Facility in Las Vegas Through its Subsidiary, Grow Contractors

Tue, 20 Jun 2017 07:30:00 EDT

HENDERSON, NV--(Marketwired - Jun 20, 2017) - mCig, Inc., (OTCQB: MCIG), a leading distributor of innovative products, technologies, and services for the global medical cannabis industry is pleased to announce that Grow Contractors (GC) has signed a management contract to staff and manage a 15,000 square foot indoor cultivation facility in Las Vegas, Nevada for R.H. Medical.




Zecotek Receives Notice of Allowance in China for New Advanced Formulation of its Worldwide Patented LFS Scintillation Crystal

Tue, 20 Jun 2017 03:15:00 EDT

SINGAPORE--(Marketwired - June 20, 2017) - Zecotek Photonics Inc. (TSX VENTURE: ZMS) (FRANKFURT: W1I) (OTC PINK: ZMSPF), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, is pleased to announce that its wholly owned division, Zecotek Imaging Systems Pte. Ltd., has received a notice of allowance in China for its advanced formulation of its patented LFS scintillation crystals. This is the second patent in a series of worldwide, pending patents, for multi-doped lutetium oxide based scintillators having improved photonic properties, known as, "LFS-M".




CV Sciences, Inc. Announces Commencement of IND preparation immediately following Pre-IND Meeting With FDA

Mon, 19 Jun 2017 13:39:39 EDT

LAS VEGAS, NV--(Marketwired - June 19, 2017) - CV Sciences, Inc. (OTCQB: CVSI) (the "Company," "CV Sciences," "our" or "we"), today announced that it held its pre-IND meeting with the U.S. Food and Drug Administration (FDA) on June 15, 2017, to review its drug development plan for CVSI-007, the Company's patent-pending product for smokeless tobacco addiction therapy consisting of nicotine-polacrilex chewing gum in combination with synthetic cannabidiol (CBD).




UPDATE - Eco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman

Mon, 19 Jun 2017 12:51:54 EDT

ECPO Chairman and CEO Addresses Shareholders Informing Them of New Business Model




GeoVax Awarded NIH Grant for Zika Vaccine

Mon, 19 Jun 2017 12:00:00 EDT

Supports Advanced Preclinical Testing in Preparation for Human Clinical Trials




OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico

Mon, 19 Jun 2017 11:55:26 EDT

MEXICO CITY, MEXICO--(Marketwired - June 19, 2017) - OncBioMune México, S.A. De C.V., (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies and owner of vaccine technology and commercialization of a portfolio of products internationally announced the completion of the acquisition of the sanitary registration and intellectual property rights of Norepinefrine (Norepinephrine) for the Mexican market from Teva Pharmaceuticals Mexico, S.A. de C.V. (Teva), the Mexican subsidiary of Teva Pharmaceuticals, Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day.




VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM)

Mon, 19 Jun 2017 08:30:00 EDT

CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 19, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has completed a pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration ("FDA") to discuss the Phase III clinical program for Sci-B-VacT, VBI's third-generation hepatitis B vaccine. Sci-B-VacT is currently approved for use in Israel and 14 other countries worldwide.




Tauriga Sciences, Inc. Reiterates That it Has No Plans to Enact Any Type of Reverse Split for the Foreseeable Future

Mon, 19 Jun 2017 08:00:00 EDT

NEW YORK, NY--(Marketwired - Jun 19, 2017) -  Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company"), a Company engaged in the building of businesses in the life sciences space, has today confirmed to shareholders that it has no plans to enact any type of Reverse Split for the foreseeable future. This press release has been issued, with Board Approval, in response to numerous shareholders inquiries over the past few weeks. The Company expects that it would only consider enacting a Reverse Split as part of some future merger/acquisition, if both parties would agree that an amendment of the Company's capital structure at that time, would be advantageous to all.




IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2017

Mon, 19 Jun 2017 08:00:00 EDT

MONTREAL, QUEBEC--(Marketwired - June 19, 2017) - IBEX Technologies Inc. ("IBEX" or the "Company") (TSX VENTURE:IBT) today reported its financial results for the nine months ended April 30, 2017.




Pharmaceutical Serialization -- Best Practices for Global Commercial Supply in an Evolving Market, New Webinar Hosted by Xtalks

Mon, 19 Jun 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - June 19, 2017) - During a live presentation on Thursday, June 29, 2017 at 10am EDT (3pm BST/UK), PCI's global head of serialization, Ian Parsonage, will share his experiences in developing PCI's serialization technology platform, along with developing and executing PCI's strategy for supplying commercial serialized products internationally including the United States, Europe and emerging markets across the globe.




Integrating eCOA and RTSM to Improve Clinical Trial Efficiency, New Webinar Hosted by Xtalks

Mon, 19 Jun 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - June 19, 2017) - The rapid expansion of the use of electronic patient-reported outcomes (ePRO) and electronic clinical outcome assessments (eCOA) in clinical trials has led to a number of exciting innovations.